Key Drivers
- Cash-heavy balance
- High cash burn
- Very low revenue
AIAI Summary
NAMS has shifted from speculative R&D to a de‑risked, event‑driven investment—its strong cash/no‑debt runway makes near‑term upside now hinge almost entirely on clean 2H26 regulatory approvals and YE26 RUBENS/Phase‑3 readouts (failure or delays would likely force dilution and sharply compress the richly priced stock), so monitor those catalysts and insider selling as the primary drivers of return/drawdown.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash-heavy balance
- •High cash burn
- •Very low revenue
NAMS is cash-rich and virtually debt-free but suffering persistent large operating losses, minimal revenue and poor asset productivity that threaten sustainability unless R&D converts to growth. #cash-rich
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Near-term support
- •Resistance band
NAMS is in a clear short-term downtrend over the last month (≈35.58 → $28.94, −18–19%), trading below the last month moving average (~$31.8) with near-term support at $28.62 and resistance at $31.0–$32.8, implying downside bias unless it reclaims that band.
Sharp ~18–19% decline from $35.58 to $28.94 over the last month
Sentiment & News
Key News Insights:
- •Significant insider selling
- •Continued investor engagement
- •Modest hiring grants
Senior NewAmsterdam executives executed large share sales (~528k shares, ~$16.9M) in late Feb–early Mar 2026 while the company continued investor outreach and granted small inducement options to new non‑executives. #insider-sales #investor-outreach
Concentrated insider liquidity likely raises short‑term sentiment pressure on the stock, though ongoing outreach and limited option grants suggest normal corporate activity rather than strategic reset
Similar Companies in Healthcare
Other companies in the same sector with AI ratings